Surfactant in SARS-CoV-2 - a therapeutic option based on underlying lung cell damage?

Autores/as

  • Maristella de Araújo Carvalho Sousa IPERBA - Instituto de Perinatologia da Bahia - Salvador - Bahia.
  • Gabriela Correia Matos de Oliveira Faculdade de Medicina – UniFTC – Salvador – Bahia – Brazil
  • Luis Jesuino de Oliveira Andrade Departamento de Saúde - Universidade Estadual de Santa Cruz - Ilhéus - Bahia.

DOI:

https://doi.org/10.9771/cmbio.v19i4.37015

Palabras clave:

Severe acute respiratory syndrome, coronavirus 2, type II pneumocytes, pulmonary surfactant.

Resumen

Introduction: the severe acute respiratory syndrome – coronavirus 2 (SARS Cov-2), leads to a diffuse alveolar deterioration due infection of type II pneumocytes. The type II pneumocytes are involved in synthesis and secretion of pulmonary surfactant in pulmonary alveoli. Objective: the purpose of this study is to discuss the indication of surfactant replacement as a potential adjunctive treatment modality for SARS CoV-2, similarly treatment to neonatal respiratory distress syndrome. Methodology: we argue that SARS can be triggered by surfactant deficiency secondary to production deficiency determined by type 2 pneumocyte injuries. In this sense, we carried out a bibliographic review. Conclusion: thus, the replacement of human surfactant could be a potential treatment modality for SARS CoV-2, in the same way that it is indicated for the treatment of neonatal respiratory distress syndrome

Descargas

Los datos de descargas todavía no están disponibles.

Publicado

2020-12-30

Cómo citar

Carvalho Sousa, M. de A., Matos de Oliveira, G. C., & de Oliveira Andrade, L. J. (2020). Surfactant in SARS-CoV-2 - a therapeutic option based on underlying lung cell damage?. Revista De Ciências Médicas E Biológicas, 19(4), 602–605. https://doi.org/10.9771/cmbio.v19i4.37015

Artículos más leídos del mismo autor/a

1 2 > >>